KUALA LUMPUR, April 1 -- Analytica Limited, the Australian manufacturer of the PeriCoach pelvic floor exercise system for the treatment of stress urinary incontinence, has entered into a joint venture (JV) agreement to manufacture, distribute and market the system in China, Macau, Hong Kong and Taiwan.
According to a statement, Analytica partners with Hebei NACOL Bio-Technology Co Ltd (Nacol) and Shijiazhuang Biosphere Pty Ltd (Biosphere), based in Hebei Province.
Nacol key shareholders include two highly experienced Chinese medical manufacturing and distribution companies, Heibei Aineng Biological Technology Co Ltd and Shijiazhuang YST Medical Supplies Co Ltd.
Analytica Ltd Chairman, Dr Michael Monsour, said: “PeriCoach is a proven cost-effective solution that will dramatically improve quality of life and burden of care for women. We look forward to the continued exploration of our strategic options to expand the availability of PeriCoach globally.”
The JV will register PeriCoach with the Chinese Food and Drug Administration (CFDA) as a class II medical device. With CFDA clearance, PeriCoach can become a prescription treatment, initially covering the hospital network in the North China area.
The agreement furthers Analytica’s strategy to bring PeriCoach into global markets, building upon growth in the Middle East with partner Motion Egypt LLC, and pursuit of other partners in North America, Europe and Southeast Asia outside of China.
Currently manufactured in Australia, the new PeriCoach manufacturing line for the Chinese market is only located in the Shijiazhuang Free Trade Zone and will be listed as one of the major projects in the free trade zone and high technology zone.
PeriCoach will be distributed through the existing extensive network of hospitals and postpartum organisations serviced by the JV partners.
More details at www.AnalyticaMedical.com.
-- BERNAMA
No comments:
Post a Comment